💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Karyopharm's selinexor shows positive effect in multiple myeloma study; shares up 2%

Published 06/15/2018, 11:06 AM
© Reuters.  Karyopharm's selinexor shows positive effect in multiple myeloma study; shares up 2%
KPTI
-
  • Updated results from a Phase 1b/2 clinical trial, STOMP, evaluating Karyopharm Therapeutics' (KPTI +2.2%) lead drug selinexor + dexamethasone, combined with Velcade (bortezomib), Pomalyst (pomalidomide) or Darzalex (daratumumab), in previously treated patients with multiple myeloma (MM) showed a treatment benefit. The data are being presented at the EHA Annual Meeting in Stockholm.
  • The objective response rate (ORR) in the selinexor/dex/bort cohort was 63%.
  • The ORR in the selinexor/dex/dara group was 68%.
  • The ORR in the selinexor/dex/pom group was 50%.
  • Selinexor has Orphan Drug and Fast Track status in the U.S. for this patient population.
  • Now read: Karyopharm Impresses In Refractory Multiple Myeloma Trial


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.